文献速递肝胆胰外科

远端胰腺切除术后淋巴结检出数目与胰腺体尾部导管腺癌淋巴结状态评估

Number of Examined Lymph Nodes and Nodal Status Assessment in Distal Pancreatectomy for Body/Tail Ductal Adenocarcinoma.
PubMed 文献 · Ann Surg · 2019-01-01

该回顾性研究纳入2000至2013年两家学术医院接受远端胰腺切除术的胰腺导管腺癌患者240例,评估检出淋巴结数目对分期和生存的影响。中位检出淋巴结数为21枚,估算确保准确检测淋巴结转移所需的最小检出淋巴结数为20枚。淋巴结检出数目≥20枚是淋巴结阴性患者的独立预后因素,提示存在分期迁移效应;在淋巴结阳性患者中,N2分期而非淋巴结比率是生存的显著预测因子。

要点

  • 远端胰腺切除治疗体尾部胰腺导管腺癌时,至少需检出20枚淋巴结以确保准确分期。
  • 淋巴结检出数目影响淋巴结分期,检出数目不足20枚可能导致分期迁移。
  • 淋巴结阳性患者中,N2分期是生存的独立预测因子,优于淋巴结比率。

核心结论

  • 淋巴结检出数目影响体尾部胰腺导管腺癌的淋巴结分期,正确分期至少需要检出20枚淋巴结。
  • 在淋巴结阳性患者中,N分期对生存的预测优于淋巴结比率。

研究设计与样本

  • 回顾性分析2000年至2013年两家学术医院接受远端胰腺切除术的胰腺导管腺癌患者240例。
  • 采用美国癌症联合委员会第八版分期系统,使用二项概率法则估算最小检出淋巴结数。
  • 分别对淋巴结阴性和阳性患者进行单变量和多变量生存分析。

主要发现

  • 中位检出淋巴结数为21枚,淋巴结阴性患者显著低于淋巴结阳性患者(18.5 vs 24.0;P=0.001)。
  • 随着检出淋巴结数目增加,淋巴结阳性患者比例升高,而淋巴结比率呈相反趋势。
  • 估算的最小检出淋巴结数为20枚。
  • 淋巴结检出数目(≥或<20枚)仅在淋巴结阴性患者中为独立预后因素(OR 3.23,检出<20枚),提示分期迁移效应。
  • 在淋巴结阳性患者中,多变量分析显示N2分期是生存的显著预测因子(OR 1.68),而淋巴结比率不是。

临床怎么用

  • 远端胰腺切除治疗体尾部胰腺导管腺癌时,应努力检出至少20枚淋巴结以保障准确分期。
  • 淋巴结阳性患者评估预后时,应关注N分期而非淋巴结比率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: First, to assess the impact of the number of examined lymph nodes (ELNs) on staging and survival after distal pancreatectomy (DP) for pancreatic adenocarcinoma (PDAC). Second, to identify the minimum number of ELNs (MNELNs) ensuring an accurate detection of nodal involvement. Third, to reappraise the role of lymph node (LN) parameters, including N-status and lymph node ratio (LNR). BACKGROUND: In contrast with pancreatoduodenectomy, information on LN staging and the MNELN required in DP is lacking. METHODS: Patients undergoing DP for PDAC at 2 academic hospitals from 2000 through 2013 were retrospectively analyzed. The eighth edition of the American Joint Committee on Cancer staging system was used. The MNELN was estimated using the binomial probability law. Survival analyses were performed separately for node-negative and node-positive patients using univariable and multivariable models. RESULTS: The study population consisted of 240 patients. The median number of ELN was 21, significantly lower in node-negative patients as compared with node-positive patients (18.5 vs 24.0; P = 0.001). The proportion of node-positive patients increased with increasing numbers of ELNs, whereas LNR showed an inverse trend. The estimated MNELN was 20. The number of ELN (≥ or <20) was an independent prognostic factor only in node-negative patients [odds ratio (OR) 3.23 for ELN <20), suggesting a stage migration effect. In node-positive patients, N2-class, but not LNR, was a significant predictor of survival at multivariable analysis (OR 1.68). CONCLUSION: The number of ELN affects nodal staging in body/tail PDAC. At least 20 LNs are required for correct staging. N-status is superior to LNR in predicting survival of node-positive patients.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Malleo G, Maggino L, Ferrone CR, et al. Number of Examined Lymph Nodes and Nodal Status Assessment in Distal Pancreatectomy for Body/Tail Ductal Adenocarcinoma. Ann Surg. 2019. PMID: 29672406. doi:10.1097/SLA.0000000000002781

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。